Table 8.
Cardiac adverse events caused by approved monoclonal antibodies used for therapy.
| Monoclonal Antibody | Cardiac Adverse Events |
|---|---|
| Adalimumab. | Heart failure |
| Ado-trastuzumab emtansine 1 | Decreased LVEF |
| Alemtuzumab | Cardiomyopathy, decreased LVEF, cardiac arrhythmias associated with infusions |
| Bevacizumab | CHF: incidence of grade 3 reaction for LVD 1% |
| Bezlotoxumab | Heart failure |
| Brentuximab vedotin | Supraventricular arrhythmia in systemic anaplastic large cell lymphoma |
| Certolizumab pegol | Heart failure |
| Cetuximab | Cardiopulmonary arrest/sudden death |
| Fam-trastuzumab deruxtecan-nxki | LVD |
| Golimumab | Heart failure |
| Ibritumomab tiuxetan | Cardiac arrest related to infusions |
| Inotuzumab ozogamicin | QT interval prolongation |
| Margetuximab-cmkb 1 | LVD |
| Necitumumab 1 | Cardiopulmonary arrest |
| Obinutuzumab | Worsening of preexisting cardiac conditions leading to fatal cardiac events |
| Pertuzumab 1 | Cardiomyopathy manifesting as CHF and decreased LVEF |
| Ramucirumab | Serious, sometimes fatal, myocardial infarction |
| Rituximab | Cardiac arrhythmias and angina, fatal cardiac failure |
| Romosozumab-aqqg 1 | Myocardial infarction, cardiac events, cardiovascular death |
| Trastuzumab 1 | Cardiomyopathy manifesting as CHF and decreased LVEF |
CHF—congestive heart failure; LVD—left ventricular dysfunction; LVEF—left ventricular ejection fraction. 1 FDA boxed warnings apply.